124 related articles for article (PubMed ID: 23341736)
1. Exenatide extended-release; clinical trials, patient preference, and economic considerations.
Doggrell SA
Patient Prefer Adherence; 2013; 7():35-45. PubMed ID: 23341736
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Wang J; Jin X; An P; Yu S; Mu Y
J Diabetes Res; 2019; 2019():8083417. PubMed ID: 31772945
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
Aroda VR; DeYoung MB
Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
[TBL] [Abstract][Full Text] [Related]
4. Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies.
Stonehouse A; Walsh B; Cuddihy R
Diabetes Technol Ther; 2011 Oct; 13(10):1063-9. PubMed ID: 21732798
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries.
Divino V; DeKoven M; Hallinan S; Varol N; Wirta SB; Lee WC; Reaney M
Diabetes Ther; 2014 Dec; 5(2):499-520. PubMed ID: 25366334
[TBL] [Abstract][Full Text] [Related]
6. A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss.
Pereira MJ; Lundkvist P; Kamble PG; Lau J; Martins JG; Sjöström CD; Schnecke V; Walentinsson A; Johnsson E; Eriksson JW
Diabetes Ther; 2018 Aug; 9(4):1511-1532. PubMed ID: 29949016
[TBL] [Abstract][Full Text] [Related]
7. Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study.
Federici MO; McQuillan J; Biricolti G; Losi S; Lebrec J; Richards C; Miglio C; Norrbacka K
Diabetes Ther; 2018 Apr; 9(2):789-801. PubMed ID: 29525885
[TBL] [Abstract][Full Text] [Related]
8. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
Guillermin AL; Lloyd A; Best JH; DeYoung MB; Samyshkin Y; Gaebler JA
J Med Econ; 2012; 15(4):654-63. PubMed ID: 22369345
[TBL] [Abstract][Full Text] [Related]
9. GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data.
Divino V; Boye KS; Lebrec J; DeKoven M; Norrbacka K
Diabetes Ther; 2019 Jun; 10(3):1067-1088. PubMed ID: 31028689
[TBL] [Abstract][Full Text] [Related]
10. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years.
Macconell L; Pencek R; Li Y; Maggs D; Porter L
Diabetes Metab Syndr Obes; 2013; 6():31-41. PubMed ID: 23358123
[TBL] [Abstract][Full Text] [Related]
11. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study.
Otto T; Myland M; Jung H; Lebrec J; Richter H; Norrbacka K
Curr Med Res Opin; 2019 May; 35(5):893-901. PubMed ID: 30328731
[TBL] [Abstract][Full Text] [Related]
12. Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.
Tzanetakos C; Bargiota A; Kourlaba G; Gourzoulidis G; Maniadakis N
Clin Drug Investig; 2018 Jan; 38(1):67-77. PubMed ID: 29080210
[TBL] [Abstract][Full Text] [Related]
13. Exenatide extended-release: a review of its use in type 2 diabetes mellitus.
Scott LJ
Drugs; 2012 Aug; 72(12):1679-707. PubMed ID: 22867046
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.
Divino V; DeKoven M; Khan FA; Boye KS; Sapin H; Norrbacka K
Diabetes Ther; 2017 Feb; 8(1):115-128. PubMed ID: 28070733
[TBL] [Abstract][Full Text] [Related]
15. Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.
Syed YY; McCormack PL
Drugs; 2015 Jul; 75(10):1141-52. PubMed ID: 26071140
[TBL] [Abstract][Full Text] [Related]
16. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.
Rosenstock J; Balas B; Charbonnel B; Bolli GB; Boldrin M; Ratner R; Balena R;
Diabetes Care; 2013 Mar; 36(3):498-504. PubMed ID: 23139373
[TBL] [Abstract][Full Text] [Related]
17. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
Minze MG; Klein MS; Jernigan MJ; Wise SL; Frugé K
Pharmacotherapy; 2013 Jun; 33(6):627-38. PubMed ID: 23553357
[TBL] [Abstract][Full Text] [Related]
18. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.
Buse JB; Garber A; Rosenstock J; Schmidt WE; Brett JH; Videbæk N; Holst J; Nauck M
J Clin Endocrinol Metab; 2011 Jun; 96(6):1695-702. PubMed ID: 21450987
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes.
Neumiller JJ; Sonnett TE; Wood LD; Setter SM; Campbell RK
Diabetes Metab Syndr Obes; 2010 Jul; 3():215-26. PubMed ID: 21437090
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
Russell-Jones D; Vaag A; Schmitz O; Sethi BK; Lalic N; Antic S; Zdravkovic M; Ravn GM; Simó R;
Diabetologia; 2009 Oct; 52(10):2046-55. PubMed ID: 19688338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
